Research programme: CCR1 antagonists - ChemoCentryx

Drug Profile

Research programme: CCR1 antagonists - ChemoCentryx

Alternative Names: CCX 634; CCX 9588

Latest Information Update: 21 Apr 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator ChemoCentryx
  • Class Small molecules
  • Mechanism of Action CCR1 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer
  • Discontinued Rheumatoid arthritis

Most Recent Events

  • 18 Apr 2016 Updated pharmacodynamics data from a preclinical trial in Breast cancer presented at American Association for Cancer Research Annual Meeting (AACR-2016) ,
  • 04 Nov 2015 Preclinical trials in Cancer in USA (unspecified route)
  • 04 Nov 2015 Pharmacodynamics data from a preclinical trial in Breast cancer released by ChemoCentryx
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top